About Us

Press Release

Contact

Search

Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Pharma

Biotech News

Biotechnology News Magazine is one of the industry’s leading sources for biotech industry news!
Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.

Biotechnology News Magazine

Biotech executives, investors, and other allied health professionals have access to Biotechnology News Magazine through a complimentary subscription. Furthermore, as patients become more pro-active in researching various medical diseases and conditions, we are proud to boast they are subscribers of our publication as well.

We hope you find value in Biotechnology News Magazine’s overall purpose and objectives. BiotechnologyNews Magazine is the authoritative voice of biotechnology, bridging the industry to healthcare professionals, academia, government, venture capitalists, and the general public.

If you have any questions or comments, please feel free to contact us.

Biotechnology News Magazine is a fast, 1,2,3, easy read! LEARN MORE.

Visit our sister publication site
Medical Device News Magazine

Medical Device News Magazine welcomes guest byline articles to inform and educate medical specialists, device industry executives, other allied health professionals, investors and more.

Articles from key opinion leaders provide great insight and in some cases, are superior over standard press releases! We invite guest contributions! Contact  mdnewsmagazine@infomeddnews.com

Latest Biotech Industry News

Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology

The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020.

ENPICOM Launches Versatile Display Aata Analysis Solution to Accelerate Antibody Selection While Maximizing Precision

The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform reports ENPICOM.

Aptamer Group and PinotBio Extend Their collaboration for Development of Optimer®-drug Conjugates

Aptamer Group and PinotBio will now work together to develop Optimer-drug conjugates as novel format ADC alternatives to four specified non-blood-based cancer biomarkers: Nectin-4, Tissue Factor, CEACAM5 and CD73

Calliditas Therapeutics Receives Positive CHMP Opinion in IgA Nephropathy

If confirmed by the European Commission (EC), Kinpeygo will be the first and only approved treatment for IgAN reports Calliditas Therapeutics.

Cepheid Receives CE Mark for Xpert® Xpress CoV-2 plus

New “plus” version of test adds a 3rd gene target to enhance detection of future SARS-CoV-2 variants notes Cepheid.

Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases

The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic.

Rune Labs Expands into Europe with Launch of Portuguese Subsidiary

Rune Labs developed StrivePD, a digital care ecosystem that enables people with Parkinson's to share their daily disease experience with their care team in between clinical visits.

EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate

Thomas Lingelbach, Chief Executive Officer of Valneva, commented, “The EMA’s acceptance of the filing for VLA2001 is an important step toward product approval.
Load more

Noteworthy Views & Opinions from Our Experts

Reduced Nicotine Content Cigarettes: A Bridge to Somewhere: By James A Mish Chief Executive Officer 22nd Century Group

Is willpower the answer to quitting cigarettes? Read what Chief Executive Officer James A. Mish of 22nd Century Group has to say.

Citius Pharmaceuticals Growth Strategy: Two Phase 3 Assets & Diversified Pipeline: By Leonard Mazur Chairman & CEO

Mr. Mazur provides details about Citius Pharmaceuticals, recent developments, and a great deal more. A must-read article.

Temporary Labs and Testing Clinics-The Covid Response from Flooring Manufacturer SelecTech

Thomas Ricciardelli, President of SelecTech: "While flooring is but one part of a temporary facility, it’s a critical one. And thankfully, the development of vaccines and better therapeutics have slowed the Covid pandemic down so temporary facilities aren’t needed. Still, it’s nice to know that in a time of crisis, there exists the resources—including flooring—to create these types of facilities in fairly short order." Read on.

Dr Juan Jofre PhD: The Growing Interest in Coliphages & Their Proven Effectiveness As Needed Viral Indicators In Water Quality Control

Dr Juan Jofre PhD writes, "In the late 1960s, it became clear that bacterial indicators used today to assess microbiological water quality are ineffective in predicting viruses' presence in water, sludge, or food matrices. Therefore, adequately detecting and monitoring viral contamination in aquatic environments became evident." Read what he has to say.

FDA Updates

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

LogicBio Therapeutics initiates activities to resume dosing.

Dimerix Reports FDA IND Approval for Phase 3 Study of DMX-200 in FSGS

FDA IND approved for ACTION3 Phase 3 clinical study, paves the way for patient recruitment in the United States reports Dimerix.

AlloVir Reports FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir advises Posoleucel’s third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies.

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

BioCardia notes the first part of the clinical trial will evaluate increasing doses of the NK1R+ MSCs and the optimal dose will be taken to Phase II in a randomized study in adult patients recovering from ARDS due to COVID-19.
Load more

Acquisitions & Mergers

Synexa Life Sciences Acquires Finnish CRO Syrinx Bioanalytics

The move is part of Synexa Life Sciences ongoing ‘buy and build’ growth strategy, aimed at building the global market leader in specialist biomarker and bioanalytical services.

Biotium Announces Acquisition of CAT5™ FFPE RNA/DNA Extraction Technology from Cell Data Sciences

RNAstorm™ and DNAstorm™ RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors notes Biotium.

DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics

DCN Dx advises the acquisition expands DCN Dx's footprint in the point-of-use testing and sampling markets in both human and veterinary verticals.

Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services

Genovac becomes Carterra’s 100th LSA placement throughout the world.
Load more

Funding

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology

OncoHost said the funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial.

Aspen Neuroscience Announces $147.5 Million Series B Financing

Will fund clinical trials of Aspen Neuroscience 1st iPSC-derived autologous dopamine neuron replacement for Parkinson's Disease.

FACIT Invests in OICR’s Groundbreaking Approaches to Integrated Drug Discovery & Cancer Informatics

FACIT notes the early-stage capital positions science and intellectual property for Ontario economic impact.

iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement

PixoTech® licensing shifted in as iXensor's new growth engine to meet self-testing strong demand in the post-pandemic era.
Load more

Clinical Trials, Studies, Data

PharmAust Reports New Australian Clinical Trial to Test a Cancer Drug to Treat Motor Neuron Disease

The Phase 1 trial will test the safety and tolerability of MPL in patients living with MND, and will look for signs that MPL can slow the progression of MND notes PharmAust.

The RSA Group Reports New Study Highlights Talent Needed to Grow the Biosimilars Sector

The RSA Group states the new report features interviews with leaders of biosimilars companies.

CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Data were presented demonstrating that seladelpar treatment throughout 2 years resulted in a decrease in PBC GLOBE score and predicted improved transplant-free survival. Read more.
Load more

Executives on the Move

Dr Paul Brooks Appointed Chief Business Officer of CN Bio

Dr Paul Brooks is an experienced C-suite level executive with over 25 years in the life science industry building businesses

Maxim Biomedical Expands Sales and Marketing Organization

Stephen Sproul has joined Maxim Biomedical as Director of Sales and Marketing and Anthony Morrison will be stepping down from his role as Chief Commercial Officer but will continue working with the company in an advisory role.

Claudio Radossi Appointed President of Pharma Equipment Leader MG America

From 1995-2015, Claudio Radossi had served as MG America’s Director of Sales, before departing to take ownership of EMSE Corporation, a leader in medical air and vacuum systems for healthcare facilities.

Jeffrey M Leiden MD PhD Appointed Odyssey Therapeutics Board Chair

Jeffrey M Leiden MD Ph.D., is an industry leader with more than 40 years' experience in the biopharma industry.
Load more

Health / Lifestyle Articles

Articles of Interest

Market Reports

Looking to advertise in a Biotech Magazine? Contact us today at BNM@bnmag1.com or 561.316.3330.

© Copyright 2022 Biotechnology News Magazine, a division of PTM Healthcare Marketing, Inc.